GlySure’s Technology May Break Barrier For Tight Control And Automated Glucose Monitoring
GlySure’s technology enables a healthcare facility to implement tight glycemic control and intensive insulin therapy.
Month: May 2011
YM BioSciences Receives Orphan Drug Designation In EU For Myelofibrosis Treatment
YM BioSciences has received orphan drug designation from the European Commission for CYT387, a treatment for myelofibrosis, a type of chronic leukemia.
Advanced Cardiac Therapeutics Studies Innovative Catheter System To Treat Arrythmias
ACT recently announced that the first patients have been enrolled in a CE Mark clinical trial of the safety and performance of the company’s TEMPASURE cardiac ablation catheter.
ReNeuron Treats Third Stroke Patient In Phase I Trials Of Stem Cell Therapy
ReNeuron said this morning the last of the stroke patients in the initial dosing group has been treated with the group’s new stem cell therapy.
InSite Vision Is Developing Treatment For Common Eye Disease Blepharitis, For Which There Is Currently No Approved Treatment
InSite Vision has reached an agreement with the FDA on a Special Protocol Assessment for the design of a Phase 3 clinical trial of treatment in patients with blepharitis.
NeoStem To Drive Shareholder Value, Says Rodman & Renshaw
NeoStem said Thursday that equity research firm Rodman & Renshaw re-iterated the multi-faceted stem cell company’s market outperform rating, based on “multiple milestones to drive shareholder value”.
Ampio Pharmaceuticals Shows Promising Results In Treating The Most Common Male Sexual Dysfunction
Premature ejaculation is a distressing male sexual dysfunction that is more common than erectile dysfunction.
Renovo Actively Progressing With Plans To Maximize Returns After Juvista Failure
Renovo Group (LON:RNVO) confirmed today it will be left with £33 million if it presses ahead with plans to reduce its headcount by 100.
ImmunoCellular To Present Encouraging Phase 1 Study Results For Brain Tumour Treatment
ImmunoCellular Therapeutics will present positive results from a phase 1 clinical study on its ICT-107 therapy, a treatment for a type of brain tumor.